title: Cerebellar ataxia associated with neuroendocrine thymic carcinoma and GAD antibodies.
authors.forename: L
authors.initials: L
authors.lastname: Bataller
authors.forename: C
authors.initials: C
authors.lastname: Valero
authors.forename: R
authors.initials: R
authors.lastname: Díaz
authors.forename: A
authors.initials: A
authors.lastname: Froufe
authors.forename: A
authors.initials: A
authors.lastname: Garcia-Zarza
authors.forename: T
authors.initials: T
authors.lastname: Ribalta
authors.forename: J J
authors.initials: JJ
authors.lastname: Vilchez
authors.forename: A
authors.initials: A
authors.lastname: Saiz
mesh_terms: D001323:Autoantibodies / Q000097:blood*; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D005968:Glutamate Decarboxylase / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology / Q000628:therapy; D009460:Neurologic Examination; D020362:Paraneoplastic Cerebellar Degeneration / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology / Q000628:therapy; D013934:Thymectomy; D013950:Thymus Gland / Q000276:immunology / Q000473:pathology; D013953:Thymus Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology / Q000628:therapy
chemical_list: D001323:Autoantibodies; D005968:Glutamate Decarboxylase